BridgeMD
Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: the MetNET-2 trial
EU CTIS ID: 2024-513200-34-00
What this study is testing
To evaluate the safety of Lanreotide ATG 120 mg in combination with Metformin as number of AEs and SAEs.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients (male or female, age > 18 years)
- Basal blood tests: - Counts of neutrophils in absolute value> 1.5 x 103 / L - Platelet count> 100 x 103 / L - Hemoglobin> 9 g/dl - Total Bilirubin <1.5 times the upper limit of normal - AST, ALT <2.5 times the upper limit of normal - Alkaline phosphatase <2.5 times the upper limit of normal - Values of serum creatinine <1.5 mg / dl. - CCr ≥ 60 mL / min
- ECOG performance status ≤ 2
- Life expectancy > 12 months
- Written informed consent
- Female subjects of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for at least 60 days after participation in the study. Acceptable methods of contraception include double barrier method [i.e. condom and occlusive cap (diaphragm or cervical/vault caps)] spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
You likely can't join if
- Surgery performed within 28 days prior to the beginning of study treatment
- Patients with a condition of metabolic acidosis, acute or chronic, including ketoacitosi
- History of POTUS (alcohol abuse), or habitual intake of alcohol (≥ 3 glasses of alcoholic drinks / day) sufficient to cause hepatotoxicity
- Severe states of dehydration
- Prolonged fasting
- History of immunosuppression, including positive HIV test
See the full eligibility criteria
Who can join
- Adult patients (male or female, age > 18 years)
- Basal blood tests: - Counts of neutrophils in absolute value> 1.5 x 103 / L - Platelet count> 100 x 103 / L - Hemoglobin> 9 g/dl - Total Bilirubin <1.5 times the upper limit of normal - AST, ALT <2.5 times the upper limit of normal - Alkaline phosphatase <2.5 times the upper limit of normal - Values of serum creatinine <1.5 mg / dl. - CCr ≥ 60 mL / min
- ECOG performance status ≤ 2
- Life expectancy > 12 months
- Written informed consent
- Female subjects of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for at least 60 days after participation in the study. Acceptable methods of contraception include double barrier method [i.e. condom and occlusive cap (diaphragm or cervical/vault caps)] spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- Male subjects with female partners of childbearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 60 days after participation in the study
- Patient with advanced disease, not resectable. The evaluation of unresectable disease will be performed by surgeon of multidisciplinary Milan ENETS Center of Excellence tumour board of Fondazione IRCCS Istituto Nazionale dei Tumori Milano.
- Patients with a histologically documented diagnosis of advanced well differentiated (G1 and G2) GI or lung carcinoids, defined according to the last WHO Classification criteria for NET
- Tumor tissue available for analysis
- Measurable disease and disease progression in the 6 months before study inclusion (according to RECIST vs 1.1), documented and appropriate imaging
- Patient who has received prior treatment with surgery or chemotherapy or somatostatin analogues or m-TOR inhibitors or other systemic antineoplastic/target therapies
- Functioning or non-functioning NETs
- Type-2 Diabetic or normoglycaemic patient
- Documented Octreoscan/PET Ga uptake/IHC stain of SSTR2 receptor, within 6 months before study entry
What rules you out
- Surgery performed within 28 days prior to the beginning of study treatment
- Patients with a condition of metabolic acidosis, acute or chronic, including ketoacitosi
- History of POTUS (alcohol abuse), or habitual intake of alcohol (≥ 3 glasses of alcoholic drinks / day) sufficient to cause hepatotoxicity
- Severe states of dehydration
- Prolonged fasting
- History of immunosuppression, including positive HIV test
- Previous or concomitant oncological pathology, except: basal cell skin cancer, in situ, as long as every other cancer patient disease-free for at least 5 years
- Serious neurological or psychiatric disorders
- Pregnancy or lactation
- Patients that do not use appropriate methods of contraception as specified in the inclusion criteria
- Brain metastasis or spinal cord compression
- Type-1 Diabetes
- Clinically significant cardiovascular disease, such as cardiovascular accidents occurred in less than 6 months, unstable angina, congestive heart failure grade greater than or equal to II (according to the classification of the New York Heart Association NYHA) series cardiac arrhythmias that require treatment
- Uncontrolled high blood pressure, atrial fibrillation
- Cardio-vascular, lung, kidney or hepatic disorders not treated/controlled
- Cirrhosis, acute hepatitis or chronic active hepatitis
- Metabolic disorders, clinical examination or laboratory investigations which contraindicate the use of drugs to study, or patients at high risk of complications from the treatment
- Active or uncontrolled severe infections
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.